Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented Flagship NB-A002 is a First-in-class DNA...
Hence then, the article about ai drug discovery pioneer nanyang biologics pte ltd enters into business combination agreement with rf acquisition corp ii in us 1 5b transaction to pursue public listing was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing )
Also on site :
- FreshRealm, Inc. Reaches Agreement with Key Customer and Initiates Chapter 11 Process to Support Ongoing Operations and Evaluate Strategic Alternatives
- AuxoAI Partners with Google Cloud to Drive Enterprise AI Transformation
- LendingClub Launches Home Improvement Financing; Begins Underwriting and Originating Loans Through Inaugural Partnership with Wisetack